P4HA1: an important target for treating fibrosis related diseases and cancer

Xuewen Yang1, Dong Zhang1, Mengmeng Li2

  • 1Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, China.

Frontiers in Pharmacology
|November 21, 2024
PubMed

Insights

Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) plays a key role in fibrosis and cancer. Targeting P4HA1 may offer new diagnostic and therapeutic strategies for these challenging diseases.

Area of Science:

  • Biochemistry
  • Oncology
  • Pathology

Background:

  • Fibrosis is a significant factor in disease progression and cancer development.
  • Current treatments for fibrosis-associated diseases and cancers lack effective targets.
  • Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is implicated in collagen synthesis and disease pathogenesis.

Purpose of the Study:

  • To systematically review the role of P4HA1 in fibrosis-related diseases and cancers.
  • To explore P4HA1 as a potential diagnostic and therapeutic target.
  • To analyze P4HA1's relevance as a biomarker.

Main Methods:

  • Systematic literature review.
  • Analysis of P4HA1's role in pathogenesis.
  • Evaluation of diagnostic and therapeutic strategies.

Main Results:

  • P4HA1 is increasingly recognized for its involvement in fibrosis and cancer.
  • Sustained P4HA1 activation is linked to collagen synthesis and disease progression.
  • P4HA1 presents potential as a biomarker and therapeutic target.

Conclusions:

  • P4HA1 is a critical factor in the pathogenesis of fibrosis-associated diseases and cancers.
  • Targeting P4HA1 offers promising avenues for novel diagnostic and therapeutic interventions.
  • Further research into P4HA1 is warranted for improved patient outcomes.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Introduction to Fibroblasts01:09

Introduction to Fibroblasts

Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
150
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
150
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
135